Antipsychotic Treatment Effects on Attention & Working Memory in Schizophrenia

抗精神病治疗对注意力的影响

基本信息

批准号：
7587619
负责人：
James L Reilly
金额：
$ 15.9万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-12-08 至 2013-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7587619
关键词：
Accounting Address Affect Aftercare Animal Model Animals Antipsychotic Agents Area Attention Base of the Brain Behavior Behavioral Brain Brain imaging Chronic Clinic Clinical Clinical Investigator Clinical Trials Clinical Trials Design Cognitive Cognitive deficits Data Data Analyses Data Collection Delusions Development Direct Costs Disease Dopamine D1 Receptor Effectiveness Event Failure Functional Magnetic Resonance Imaging Goals Hallucinations Human Image Impaired cognition Individual Investigation K-Series Research Career Programs Knowledge Laboratories Laboratory Study Learning Location Maintenance Memory impairment Mental disorders Methodology Modeling Neurobehavioral Manifestations Neurocognitive Neurocognitive Deficit Neuropharmacology Noise Operative Surgical Procedures Patients Performance Pharmaceutical Preparations Pharmacological Treatment Pharmacotherapy Population Prefrontal Cortex Prevalence Productivity Public Health Receptor Activation Regulation Research Research Activity Research Personnel Role Schizophrenia Sensory Series Short-Term Memory Support System Symptoms System Techniques Testing Time Training Translating Validation Work base behavioral pharmacology career career development cognitive function cognitive neuroscience comparative trial design distraction drug development experience first episode schizophrenia functional disability investigator training memory process mental representation neocortical neuroimaging novel oculomotor prevent programs public health relevance relating to nervous system response role model skills standard care success tool treatment effect

项目摘要

DESCRIPTION (provided by applicant): Deficits in attention and working memory, the abilities that allow individuals to selectively attend to and mentally maintain and manipulate information to guide behavior, are considered to be central components to the cognitive dysfunction in schizophrenia. While advances in antipsychotic pharmacotherapy have resulted in important gains for treating symptoms of hallucinations and delusions, cognitive deficits have been far less responsive to standard treatments. Developing novel pharmacological agents to target these persistent cognitive deficits is an important goal of ongoing schizophrenia treatment research. This is a broad and multidimensional problem involving drug development and translational animal models. In the end, success will depend on the ability of trained investigators who have the expertise and tools to evaluate drug effects on neurocognitive systems in the clinic. The aim of this proposed career development program is to facilitate the candidate's efforts to become a successful independent clinical investigator in this area. Primary objectives of this career development program are to provide the candidate with advanced training in three main areas: (1) functional brain imaging; (2) cognitive neuroscience and neuropharmacological models of working memory; and (3) clinical trial design and methodology. Research activities will focus on designing and conducting behavioral and event-related functional neuroimaging studies of working memory and attention using paradigms translated from animal models to examine antipsychotic treatment effects on these core cognitive deficits in schizophrenia. These activities will prepare the candidate for an independent program of research examining disturbances in functional brain systems that underlie cognitive impairments in schizophrenia and how these are impacted by antipsychotic treatments. The knowledge and skills gained from proposed training and research activities will be important for the Pi's career objective to use integrative approaches to investigate the effectiveness of pharmacological treatments developed to reduce cognitive impairments in schizophrenia. PUBLIC HEALTH RELEVANCE Schizophrenia is a debilitating psychiatric disorder. With a prevalence of 1% of the population and billions of dollars expended annually in direct costs and lost productivity, it is a major public health concern. Cognitive symptoms, which are not adequately treated, account for much of the long-term functional disability, and the need to understand the brain basis of these deficits is imperative to advance treatments for this disorder.

描述（由申请人提供）：注意力和工作记忆的缺陷，允许个人有选择地参加并在精神上维护和操纵信息以指导行为的能力被认为是精神分裂症认知功能障碍的核心组成部分。尽管抗精神病药物药物疗法的进步导致了治疗幻觉和妄想症状的重要增长，但认知缺陷对标准疗法的反应却大大降低。开发新型的药理学剂来瞄准这些持续的认知缺陷是正在进行的精神分裂症治疗研究的重要目标。这是一个涉及药物开发和转化动物模型的广泛而多维的问题。最后，成功将取决于训练有素的研究人员的能力，他们具有评估诊所神经认知系统的药物影响的专业知识和工具。这项拟议的职业发展计划的目的是促进候选人成为该领域成功的独立临床研究者的努力。该职业发展计划的主要目标是为候选人提供三个主要领域的高级培训：（1）功能性脑成像；（2）工作记忆的认知神经科学和神经药理模型；（3）临床试验设计和方法论。研究活动将着重于设计和进行行为和事件相关的功能神经影像学研究，以使用动物模型翻译的范式来研究工作记忆和注意力，以检查对精神分裂症中这些核心认知缺陷的抗精神病药治疗效果。这些活动将使候选人为研究的独立研究计划做好研究，以研究精神分裂症认知障碍的功能性脑系统中的干扰以及如何受到抗精神病药的影响。从建议的培训和研究活动中获得的知识和技能对于PI的职业目标来说将很重要，即使用综合方法来研究开发的药理学治疗的有效性，以减少精神分裂症的认知障碍。公共卫生相关性精神分裂症是一种使人衰弱的精神病。由于人口的1％的盛行，并且每年以直接成本和生产率失去花费数十亿美元，这是一个主要的公共卫生问题。认知症状没有得到充分治疗，占长期功能障碍的大部分内容，并且必须了解这些缺陷的大脑基础的需求是促进这种疾病的治疗方法。